COMP <GO>
INCY vs MEDP // EV/EBITDA & P/E VALUATION
Incyte Corp. (NASDAQ) VS. Medpace Holdings Inc. (NASDAQ) • 15-METRIC TALLY: INCY 11
— MEDP 1
▲ EV/EBITDA & P/E VALUATION LEADER: INCY
LAST: $120.39 (+3.07%) • MKT CAP: $23.68B
valuation
12.5x
LAST: $652.01 (-3.77%) • MKT CAP: $18.95B
valuation
34.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INCY VS. MEDP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INCY | MEDP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 92.80% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 42.40% | 27.90% | +14.50 | INCY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 12.5x | 34.0x | -21.50 | INCY | /valuation <GO> |
| Free Cash Flow Yield | 4.99% | 3.60% | +1.39 | INCY | /fcf-yield <GO> |
| Operating Margin | 29.50% | 21.10% | +8.40 | INCY | /operating-margins <GO> |
| Net Profit Margin | 25.00% | 17.80% | +7.20 | INCY | /net-margins <GO> |
| Revenue Growth (YoY) | 21.20% | 20.00% | +1.20 | INCY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 10.04 | 9.13 | +0.91 | INCY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | INCY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.0 | 61.2 | -11.20 | MEDP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | 1.00 | +0.01 | INCY | /macro-sensitivity <GO> |
| Forward P/E Multiple | 15.5x | 35.3x | -19.80 | INCY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $23.68B | $18.95B | $4.72B | INCY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INCY REV | MEDP REV | INCY GROSS % | MEDP GROSS % | INCY FCF | MEDP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.14B | $2.53B | 92.8% | — | $1.18B | $681.9M |
| FY 2024 | $4.24B | $2.11B | 92.6% | — | $144.5M | $572.3M |
| FY 2023 | $3.70B | $1.89B | — | — | $330.2M | $348.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INCY // BETA 1.01
MEDP // BETA 1.00